{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:32:03Z","timestamp":1756189923949,"version":"3.40.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jns.2015.01.032","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T20:32:56Z","timestamp":1422477176000},"page":"110-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (Xeomin\u00ae) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (Dysport\u00ae)"],"prefix":"10.1016","volume":"350","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-2336","authenticated-orcid":false,"given":"Christoph","family":"Kamm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0572-3956","authenticated-orcid":false,"given":"Friederike","family":"Sch\u00fcmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eilhard","family":"Mix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiner","family":"Benecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jns.2015.01.032_bb0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1468-1331.2011.03559.x","article-title":"Five-year experience with incobotulinumtoxinA (Xeomin\u00ae): the first botulinum toxin drug free of complexing proteins","volume":"19","author":"Dressler","year":"2012","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.jns.2015.01.032_bb0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00702-014-1165-7","article-title":"IncobotulinumtoxinA (Xeomin\u00ae) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport\u00ae)","volume":"121","author":"Dressler","year":"2014","journal-title":"J Neural Transm"},{"issue":"5","key":"10.1016\/j.jns.2015.01.032_bb0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","article-title":"Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity","volume":"116","author":"Muller","year":"2009","journal-title":"J Neural Transm"},{"issue":"19","key":"10.1016\/j.jns.2015.01.032_bb0020","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2015.01.032_bb0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","article-title":"Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin\u00ae) injections in blepharospasm","volume":"120","author":"Truong","year":"2013","journal-title":"J Neural Transm"},{"issue":"2","key":"10.1016\/j.jns.2015.01.032_bb0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","article-title":"Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae","volume":"10","author":"Frevert","year":"2010","journal-title":"Drugs R D"},{"issue":"4","key":"10.1016\/j.jns.2015.01.032_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000646","article-title":"Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins \u2014 a single cohort 4-year follow-up study","volume":"2","author":"Hefter","year":"2012","journal-title":"BMJ Open"},{"issue":"Suppl. 2","key":"10.1016\/j.jns.2015.01.032_bb0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2009.02877.x","article-title":"Routine use of Xeomin in patients previously treated with Botox: long term results","volume":"16","author":"Dressler","year":"2009","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.jns.2015.01.032_bb0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1468-1331.2011.03560.x","article-title":"Editorial comment on \u20185year experience with incobotulinumtoxinA (Xeomin\u00ae) the first botulinum toxin drug free of complexing proteins\u2019","volume":"19","author":"Aoki","year":"2012","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.jns.2015.01.032_bb0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J Neural Transm"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15000507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15000507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T19:50:55Z","timestamp":1537905055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X15000507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":10,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0022510X15000507"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2015.01.032","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (Xeomin\u00ae) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (Dysport\u00ae)","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2015.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}